Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
Clinical trial NCT05568719 · RECRUITING
Trial details
- NCT number
- NCT05568719
- Sponsor
- Pfizer
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-12-28
- Primary completion
- 2040-02-25
- Enrollment
- 173
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.